A Phase 2 interventional study of Alpha-1 HC 100 mg and Placebo in Cystic Fibrosis, sponsored by Grifols Therapeutics LLC. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-08.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 717 studies in Cystic Fibrosis with a site in United States — 86 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.
Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 283rd largest by enrollment of the 517 interventional ones that give a count, is one of 31 that started in 2012, is one of 103 in phase 2, and was the 248th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →86 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 3–18
Ghady Haidar · Sites in United States
Ages 18+
Anagram Therapeutics, Inc. · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
717 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 143 · Phase 3 108 · Phase 4 47
First in 1988; this study’s year is marked. 31 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 36 across the 517 interventional studies, 80 across the 193 observational. Of the 569 that completed or were terminated, 263 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
250 of 717 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Grifols has 2 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
43 of the studies in Cystic Fibrosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413368Phase 3Children's Hospital Los AngelesMaralixibat in Patients With Cystic Fibrosis and Constipation | 2027-06-30 |
| NCT06449677Phase 3Jaeb Center for Health ResearchBionic Pancreas in CFRD | 2027-06-30 |
| NCT06996951Phase 3Indiana UniversitySinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | 2027-07 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 717 studies in Cystic Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a randomized, double-blind, placebo-controlled, dose escalation study to assess the safety and tolerability of 100 mg and 200 mg of inhaled Alpha-1 HC administered once a day for three weeks in subjects aged 18 years and older with cystic fibrosis (CF). The treatment duration in this study was intended to provide multi-dose safety information prior to proceeding to longer durations of exposure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
Biological: Alpha-1 HC 100 mg
200 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
Biological: Alpha-1 HC 200 mg
Placebo inhaled daily via nebulizer for 3 weeks. Placebo (phosphate buffer saline with polysorbate).
Biological: Placebo
Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
Also known as: Alpha1-proteinase inhibitor, alpha1-antitrypsin
Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
Also known as: Alpha1-proteinase inhibitor, alpha1-antitrypsin
Adverse Events
adverse event frequency
Time frame: 3 weeks
Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3
FEV1 conducted before and after inhalation of the investigational product at study visits.
Time frame: 3 weeks
Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 3
FVC conducted before and after inhalation of the investigational product
Time frame: 3 weeks
A total of 41 subjects provided informed consent and were screened for the study. Eleven (11) subjects were screen failures, and a total of 30 subjects were randomized to one of three treatment groups: 200 mg or 100 mg of Alpha-1 HC or placebo daily.
| Milestone | Alpha-1 HC 100 mg | Alpha-1 HC 200 mg | Placebo |
|---|---|---|---|
| Started | 10 | 10 | 10 |
| Completed | 10 | 10 | 10 |
| Not completed | 0 | 0 | 0 |
adverse event frequency
| percentage of participants | Alpha-1 HC 100 mg | Alpha-1 HC 200 mg | Placebo |
|---|---|---|---|
| Adverse Events | 100 | 80 | 60 |
FEV1 conducted before and after inhalation of the investigational product at study visits.
| percent | Alpha-1 HC 100 mg | Alpha-1 HC 200 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 | 1.5 ± 5.20 | -2.1 ± 12.28 | 0.5 ± 5.91 |
FVC conducted before and after inhalation of the investigational product
| percent | Alpha-1 HC 100 mg | Alpha-1 HC 200 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 3 | 1.2 ± 5.23 | -2.3 ± 11.57 | -0.9 ± 3.73 |
Collected over 3 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alpha-1 HC 100 mg | — | 1/10 (10%) | 10/10 (100%) |
| Alpha-1 HC 200 mg | — | 1/10 (10%) | 8/10 (80%) |
| Placebo | — | 1/10 (10%) | 6/10 (60%) |
| Event | Alpha-1 HC 100 mg | Alpha-1 HC 200 mg | Placebo |
|---|---|---|---|
| ABDOMINAL PAINGastrointestinal disorders | 0/10 | 1/10 | 0/10 |
| PULMONARY EXACERBATION/Respiratory, thoracic and mediastinal disorders | 1/10 | 0/10 | 1/10 |
| Event | Alpha-1 HC 100 mg | Alpha-1 HC 200 mg | Placebo |
|---|---|---|---|
| HAEMOPTYSISRespiratory, thoracic and mediastinal disorders | 4/10 | 1/10 | 1/10 |
| COUGHRespiratory, thoracic and mediastinal disorders | 3/10 | 1/10 | 1/10 |
| PULMONARY EXACERBATIONRespiratory, thoracic and mediastinal disorders | 1/10 | 3/10 | 0/10 |
| WHEEZINGRespiratory, thoracic and mediastinal disorders | 3/10 | 1/10 | 0/10 |
| CHEST DISCOMFORTGeneral disorders | 0/10 | 2/10 | 1/10 |
| C-REACTIVE PROTEIN INCREASEDInvestigations | 0/10 | 2/10 | 0/10 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 0/10 | 0/10 | 2/10 |
| PYREXIAGeneral disorders | 0/10 | 0/10 | 2/10 |
| MOUTH ULCERATIONGastrointestinal disorders | 1/10 | 0/10 | 0/10 |
| VOMITINGGastrointestinal disorders | 0/10 | 1/10 | 0/10 |
Intent-To-Treat (ITT) Population: included all subjects who were randomized (included those withdrawn from treatment for any reason).
| Age, Continuous(years) | Alpha-1 HC 100 mg | Alpha-1 HC 200 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 28.2 ± 10.62 | 28.1 ± 11.43 | 29.3 ± 9.96 | 28.5 ± 10.32 |
| Sex: Female, Male(Participants) | Alpha-1 HC 100 mg | Alpha-1 HC 200 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 8 | 6 | 6 | 20 |
| Male | 2 | 4 | 4 | 10 |
| Region of Enrollment(participants) | Alpha-1 HC 100 mg | Alpha-1 HC 200 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 10 | 10 | 10 | 30 |
The record gives a start of Aug 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin